hes related family bHLH transcription factor with YRPW motif 2Genealiases: CHF1 · GRIDLOCK · GRL · HERP1 · HESR2 · HRT2
Q-omics provides the consensus-scored HEY2 profile across patient tissues and cancer cell-line models. HEY2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, HEY2 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, HEY2 RNA expression shows 14,977 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, THCA, and TGCT as cancer lineages where HEY2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HEY2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HEY2 survival associations across molecular data types. HEY2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HEY2 RNA expression–survival associations across cancer types. High HEY2 expression shows unfavorable associations in MESO and COAD, but favorable associations in KIRC, UCEC, THCA and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for HEY2 RNA expression.
This table summarizes HEY2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for HEY2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HEY2 shows lower tumor expression in KICH, BLCA, LUAD and BRCA and higher tumor expression in THCA and KIRC. The THCA box plot shows higher HEY2 RNA expression in tumor versus normal tissue (log2 FC = +1.685, t-test p < 0.001).
This table shows molecular features associated with HEY2 in patient tissues and cancer cell lines. In patient samples, HEY2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, HEY2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LIVER and SKIN.
